STOCK TITAN

Intra-Cellular Therapies Inc - ITCI STOCK NEWS

Welcome to our dedicated news page for Intra-Cellular Therapies (Ticker: ITCI), a resource for investors and traders seeking the latest updates and insights on Intra-Cellular Therapies.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Intra-Cellular Therapies's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Intra-Cellular Therapies's position in the market.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.08%
Tags
conferences
-
Rhea-AI Summary
Intra-Cellular Therapies announces CAPLYTA data presentations at ASCP Annual Meeting
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.08%
Tags
none
-
Rhea-AI Summary
Intra-Cellular Therapies, Inc. announces Q1 2023 financial results with total revenues of $95.3 million and net product sales of CAPLYTA at $94.7 million, representing a 173% increase. CAPLYTA total prescriptions increased by 159% compared to Q1 2022. Study 403 shows positive results for lumateperone in patients with major depressive disorder and bipolar depression. Reiterates CAPLYTA 2023 net product sales guidance of $430 to $455 million.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.02%
Tags
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.16%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.41%
Tags
conferences earnings
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.63%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.59%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.25%
Tags
conferences earnings
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.31%
Tags
conferences
Intra-Cellular Therapies Inc

Nasdaq:ITCI

ITCI Rankings

ITCI Stock Data

6.38B
94.59M
2.51%
99.05%
3.58%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
New York

About ITCI

intra-cellular therapies is a company based out of 3960 broadway, new york, new york, united states.